directly to content (skip navigation)

---

•     
• Forum
• Guidelines
• News
• Lectures
• Contact
• Data Protection
• Sitemap

Latest twenty posts

• Higher-order cross­overs [Power / Sample Size]: sweiner 02:34 ago
• Bioequivalence Acceptance criteria for in-vitro binding study in EMA submission [Regulatives / Guidelines]: Biostats 2 days 11:05 ago
• Thanks! [Regulatives / Guidelines]: fno 3 days 04:36 ago
• Purpose of the study? [Power / Sample Size]: Helmut 3 days 05:36 ago
• Relax [Regulatives / Guidelines]: Helmut 3 days 07:25 ago
• Higher-order cross­overs [Power / Sample Size]: sweiner 3 days 23:02 ago
• No BE between early phase and Phase 3 formulations [Regulatives / Guidelines]: fno 4 days 02:13 ago
• No BE between early phase and Phase 3 formulations [Regulatives / Guidelines]: Helmut 4 days 03:09 ago
• FDA: required BE between early phase and Phase 3 formulations? [Regulatives / Guidelines]: fno 4 days 03:46 ago
• What are we doing here? [Off Topic]: nobody 6 days 03:01 ago
• What are we doing here? [Off Topic]: Helmut 6 days 03:32 ago
• What are we doing here? [Off Topic]: ElMaestro 6 days 08:52 ago
• What are we doing here? [Off Topic]: nobody 6 days 09:04 ago
• Sample size calculations [Power / Sample Size]: GM 6 days 12:25 ago
• Sample size calculations [Power / Sample Size]: Helmut 8 days 17:53 ago
• Sample size calculations [Power / Sample Size]: GM 9 days 05:42 ago
• FDA, again [R for BE/BA]: Helmut 17 days 03:20 ago
• Pre-dose samples [Design Issues]: Helmut 17 days 06:48 ago
• Subject replacement [Design Issues]: Ohlbe 18 days 08:43 ago
• Steady State Bioequivalence Study [Design Issues]: Pharma_88 18 days 09:17 ago

Data are current with Sunday, 26 January 2020 19:24 CET (Europe/Vienna; UTC +01:00).
Activity in the forum: 24 visitors (24 guests [including 9 identified bots]).